DBV Technologies (DBVT) Shares Outstanding (Diluted Average) (2021 - 2026)
DBV Technologies (DBVT) reported Shares Outstanding (Diluted Average) of $428.3 million for Q1 2026, up 317.38% year-over-year from $102.6 million in Q1 2025, and up 206.86% on a QoQ basis from $139.6 million in Q4 2025.
DBV Technologies (DBVT) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $428.3 million in Q1 2026.
- Quarterly Shares Outstanding (Diluted Average) rose 317.38% year-over-year to $428.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $428.3 million (up 317.38% YoY) and the FY2025 annual result came in at $139.6 million, up 43.9% from the prior year.
- Shares Outstanding (Diluted Average) rose to $428.3 million in Q1 2026 per DBVT's latest filing, from $139.6 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $428.3 million in Q1 2026 and bottomed at $54.9 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $96.2 million (2024), against an average of $115.2 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) climbed 0.12%; it then surged 317.38% in 2026.
- Tracing DBVT's Shares Outstanding (Diluted Average) over 5 years: stood at $77.4 million in 2022, then increased by 22.92% to $95.1 million in 2023, then climbed by 1.97% to $97.0 million in 2024, then surged by 43.9% to $139.6 million in 2025, then surged by 206.86% to $428.3 million in 2026.
- Per Business Quant, the three latest DBVT Shares Outstanding (Diluted Average) figures stand at $428.3 million (Q1 2026), $139.6 million (Q4 2025), and $124.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 428.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428.30 Mn |
| Dec 31, 2025 | 139.57 Mn |
| Sep 30, 2025 | 124.72 Mn |
| Jun 30, 2025 | 134.48 Mn |
| Mar 31, 2025 | 102.62 Mn |
| Dec 31, 2024 | 97.00 Mn |
| Sep 30, 2024 | 96.19 Mn |
| Jun 30, 2024 | 96.18 Mn |
| Mar 31, 2024 | 96.18 Mn |
| Dec 31, 2023 | 95.12 Mn |
| Sep 30, 2023 | 96.08 Mn |
| Jun 30, 2023 | 94.15 Mn |
| Mar 31, 2023 | 93.97 Mn |
| Dec 31, 2022 | 77.38 Mn |
| Sep 30, 2022 | 71.78 Mn |
| Jun 30, 2022 | 60.49 Mn |
| Mar 31, 2022 | 54.93 Mn |
| Dec 31, 2021 | 54.92 Mn |
| Sep 30, 2021 | 54.95 Mn |
| Jun 30, 2021 | 54.89 Mn |